Status and phase
Conditions
Treatments
About
Biodistribution, pharmacokinetics, and safety of F-18 THK-5351 PET in Alzheimer's disease patients and healthy subjects.
Full description
Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably Alzheimer's dementia patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Healthy Inclusion Criteria:
Patients with AD Inclusion Criteria:
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
24 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal